We suggest that the DFN approach is more suitable for MFC-MRD monitoring after CD19-directed immunotherapy, and then for searching for LAIPs, considering that patients could be heavily pretreated (especially R/R patients) and that the tumor phenotype could also be changed by immunotherapy itself. Here, CD19 is linked to neoplasm.